Purpose: Understanding etiologic heterogeneity of ovarian cancer is important for improving prevention, early detection and therapeutic approaches. We evaluated 14 hormonal, reproductive, and lifestyle factors by histologic subtype in the Ovarian Cancer Cohort Consortium (OC3).
Introduction
Ovarian cancer is the most lethal gynecologic cancer, with over 152,000 deaths world-wide each year (1) . Most ovarian cancers are detected at late stage and have a poor prognosis. Screening for ovarian cancer did not reduce mortality in two large screening trials (2, 3) . Understanding the etiologic heterogeneity of ovarian cancer is critical for development of new prevention strategies.
Although multiple carcinogenic mechanisms for ovarian tumorigenesis have been hypothesized, including incessant ovulation, hormonal stimulation, and chronic inflammation (4-7), the etiology of ovarian cancer is not well understood in part due to its heterogeneous nature. Disease subtypes have been categorized by putative precursor lesions, mutations, and histology (8, 9).
Low-grade serous, mucinous, clear cell, and endometrioid tumors are thought to arise from inclusion cysts or implants in the ovarian surface epithelium and have K-RAS, B-RAF, or P-TEN mutations. High-grade serous tumors, characterized by TP53 mutations, are thought to arise in the fallopian tube or ovarian epithelium, are more aggressive and have poorer outcomes than other types (8-10). Due to limited power, individual epidemiologic and biomarker studies usually have considered risk factor associations for all ovarian tumors together. Recently, individual cohorts and individual-level meta-analyses of primarily case-control studies have reported differential associations by subtype for menopausal hormone therapy (HT) use, oral contraceptive (OC) use, parity, smoking and body mass index (BMI) (11-17). To establish etiologic models accounting for ovarian cancer heterogeneity, there is a need for a unified prospective evaluation of multiple ovarian cancer risk factors accounting for heterogeneity. In the Ovarian Cancer Cohort Consortium (OC3) we evaluated associations of 14 key risk factors with invasive epithelial ovarian cancer risk overall and by histologic subtype based on pooled individual-level data from 5,584 invasive ovarian cancer cases from a combined cohort of over 1.3 million women enrolled in 21 studies.
Methods

Study population
The analysis included women participating in 21 prospective cohort studies from North America, Asia, and Europe (Table 1) . Prospective follow-up of ovarian cancer endpoints through questionnaires, medical records or cancer registries, as well as follow-up for death were required for participation. Minimal required information included age at study entry, OC use, and parity.
All studies obtained institutional approval for cohort maintenance and participation in the OC3.
The OC3 Data Coordinating Center and analytic approaches were approved by the institutional review board of the Brigham and Women's Hospital (BWH).
Exposure definitions
Full baseline cohort data (19 studies) or case-cohort datasets with weights for subcohort members (2 studies) were harmonized centrally. Exposures included: parity (ever vs. never, number of births: per 1 birth; 1, 2, 3, 4+ births), OC use (ever vs. never, duration of use: per 5 years of use; never, ≤1, >1-≤5, >5-≤10, >10 years), duration of breastfeeding (per 1 year among parous women), age at menarche (per 1 year; ≤11, 12, 13, 14, ≥15 years), age at natural menopause (postmenopausal women only: per 5 years; ≤40, >40-≤45, >45-≤50, >50-≤55, >55 years), menopausal HT use (ever vs. never, duration of use: per 1 year; never, ≤5, >5 years), tubal ligation (ever vs. never), hysterectomy (ever vs. never), endometriosis (ever vs. never), first degree family history of breast cancer (ever vs. never), first degree family history of ovarian cancer (ever vs. never), >10-20, >20-35, >35 pack-years). Studies that did not collect information on a specific risk factor were excluded from the analysis of that factor (Supplemental Table 1 ), leading to different samples sizes for each variable (Supplemental Table 2 ).
Outcome definitions
Epithelial ovarian or peritoneal cancer cases were confirmed through cancer registries or medical record review (ICD9: 183, 158; ICD10: C56). We evaluated associations of risk factors with all invasive epithelial cancers combined (n=5,584). Next, we evaluated associations with the four most common histologic types of invasive epithelial ovarian cancers (n=4,584): serous/poorly differentiated, endometrioid, mucinous, and clear cell. 1,000 cases had another histology or were missing histology information. Serous tumors were further subdivided by grade (well-, moderately-, poorly-differentiated, unknown).
Statistical methods
Women with a history of cancer (other than non-melanoma skin cancer), with bilateral oophorectomy prior to study entry, or missing age at baseline were excluded. We calculated hazard ratios (HR) and 95% confidence intervals (95% CI) using competing risks Cox proportional hazards regression to evaluate associations between exposures and ovarian cancer endpoints (18). Follow-up time was time between study entry and date of 1) ovarian cancer diagnosis, 2) death, or 3) end of follow-up, whichever occurred first. In primary analyses, we pooled data from all cohorts, and stratified on year of birth and cohort to account for potential differences in baseline hazards by these factors. Statistical heterogeneity of associations across subtypes was assessed via a likelihood ratio test comparing a model allowing the association for the risk factor of interest to vary by histology versus one not allowing the association to vary (16). We also used random effects meta-analysis to combine cohort-specific estimates and assess between-study heterogeneity. All models were adjusted for age at entry, number of children, and duration of OC use, unless the exposure of interest was collinear with these factors.
Hysterectomy analyses were additionally adjusted for HT use. For missing data in covariates, we included a missing indicator in the model. The Sister Study was excluded from analyses of family history as all participants had a family history of breast or ovarian cancer. To evaluate our primary models sufficiently accounted for confounding, we performed a model adjusting for all exposures together (using missing indicators when needed). In 17 studies, grade was available for at least some serous cases. We conducted similar analyses among serous tumors comparing risk factors for well-, moderately-, and poorly-differentiated tumors, and unknown grade. We performed unsupervised hierarchical clustering of the four subtypes (with and without separating serous tumors by grade) using beta estimates for all exposures except for duration of breastfeeding (not significantly associated with any of the 4 subtypes) using complete linkage and uncentered correlation (Pearson's coefficient). SAS 9.1 was used to conduct the analyses and a p-value of <0.05 was considered statistically significant.
Results
Study population
Among 1,284,586 participants (1,381,275 including full cohort size for case-cohort studies), 5,584
invasive epithelial ovarian cancers were identified during follow-up. Case numbers ranged from 1,281 for breastfeeding to 5,523 for OC use (Supplemental Table 2 ). 
Associations of hormonal and reproductive factors
Most reproductive and hormonal risk factors, except for breastfeeding, were associated with ovarian cancer risk overall ( 
Associations of other risk factors
Family history of both breast and ovarian cancer and height, but not smoking or BMI were significantly associated with ovarian cancer risk overall ( 
Associations by subtypes of serous carcinomas
Among serous tumors, moderately-and poorly differentiated carcinomas had similar associations, while associations for well-differentiated carcinomas were qualitatively different.
However, the heterogeneity was not significant for most individual factors ( 
Meta-analysis and heterogeneity across studies
Results for meta-analyses were similar to the pooled analyses (Supplemental Table 3 ). We observed little heterogeneity in associations across studies (p<0.01 for only 20 of 188 comparisons). Sixteen of these were for continuous variables, but the categorical associations did not show heterogeneity. Family history of ovarian cancer showed heterogeneity for all 4 subtypes across studies, likely due to the small number of exposed cases in many studies. Results were similar when including women with a history of cancer at baseline or when all exposures were included in the model (data not shown).
Integrated analysis of risk factors in ovarian cancer subtypes
Each subtype had unique patterns of risk factor associations ( Figure 1 ). The strongest associations for most factors were observed for endometrioid and clear cell tumors.
Unsupervised clustering divided the four histologic subtypes into two major groups ( Figure 1A ).
Serous carcinomas were separate from the other three subtypes (Pearson correlation 0.18).
Endometrioid Our results suggest that currently hypothesized, unifying mechanisms, such as incessant ovulation (4), do not apply equally to ovarian cancers. Several variables that determine a woman's lifetime number of ovulations had significant heterogeneity across subtypes. Only parity and height were associated with all subtypes, suggesting a common biologic effect (22).
Notably, mucinous tumors were not associated with any ovulation-related factors except parity, suggesting a more distinct etiology.
Ovarian cancer subtypes share some risk factors with other cancer sites. The inverse association between smoking and clear cell ovarian carcinomas is similar to that for endometrial cancer (23).
Mucinous ovarian cancers share histologic appearance and an association with smoking with colorectal cancers (24). Serous ovarian cancers had weaker associations with most hormonal and reproductive factors compared to non-serous cancers (with the exception of OC use), similar to associations for hormone receptor negative breast cancers (25). These similarities of risk factor associations across cancers mirror molecular data showing that tumor subtypes from different organs may be more similar to each other on the molecular level compared to other subtypes at the same site (e.g., high-grade serous ovarian cancer and basal-like breast cancer) (26).
While the subtype-specific associations observed in our study strongly corroborate the etiologic heterogeneity of ovarian cancers, a purely histology-based classification of endpoints may have limitations (27). Histologic evaluation is subjective and pathology practice changes over time, which could affect subtype distributions by location and year of diagnosis. We observed the most heterogeneity between studies for mucinous tumors, possibly related to temporal and geographic differences in defining mucinous tumors. However, overall, we did not observe significant Unsupervised hierarchical clustering of the (A) four subtypes and (B) including the serous subtype subdivided into well-moderately-and poorly differentiated carcinomas using the beta estimates, complete linkage, and an uncentered correlation similarity metric. The categories used in the cluster analysis were ever vs. never parous, ever vs. never OC use, ever vs. never tubal ligation, ever vs. never endometriosis, age at menarche >15 years vs. <=11 years, age at menopause <40 years vs. 50-55 years, ever vs. never menopausal HT use, ever vs. never hysterectomy, family history of breast cancer (yes vs. no), family history of ovarian cancer (yes vs. no), BMI >35 vs. 20-25, height (per 5cm increase) and ever vs. never smoking. The color scale shows the range of beta values for each exposure. d The Nurses' Health Study was broken into two study periods (1980-June 1996 and July 1996-2010) because the follow-up was nearly twice as long as any other study. We updated the exposures in 1996 for that follow-up period. 0.01 a Stratified on birth year and cohort, and adjusted for age at study entry, parity, and duration of oral contraceptive use (except when parity or oral contraceptive use was the primary exposure of interest and then we adjusted only for the other risk factor) using pooled analyses of all cohorts combined. b Assessed using a likelihood ratio test comparing a Cox proportional hazards competing risks model allowing the association to vary by histologic subtype to a model forcing the association to be the same across subtypes. c Parous women only. d Postmenopausal women only. e Additionally adjusted for duration of hormone therapy use. Stratified on birth year and cohort, and adjusted for age at study entry, parity, and duration of oral contraceptive use (except when parity or oral contraceptive use was the primary exposure of interest and then we adjusted only for the other risk factor) using a pooled analysis of all cohorts combined. b Assessed using a likelihood ratio test comparing a Cox proportional hazards competing risks model allowing the association to vary by histologic subtype to a model forcing the association to be the same across subtypes. Stratified on birth year, and adjusted for age at study entry, parity, and duration of oral contraceptive use (except when parity or oral contraceptive use was the primary exposure of interest and then we adjusted only for the other risk factor). b Meta-analysis p-heterogeneity across studies <0.01 using the q-statistic from a random-effects meta-analysis.
c Parous women only. 
